News | February 16, 2024
Glenmark Pharma posts Q3 FY24 net loss of Rs. 331 Cr
he lower sales in the current quarter are mainly on account of a one?time impact on the company’s India business
he lower sales in the current quarter are mainly on account of a one?time impact on the company’s India business
The talk show will be held monthly via Medanta's YouTube, Facebook and LinkedIn channe
The CDCCs are strategically positioned in regions identified as high-impact areas
This recognition attests to Sun Pharma’s commitment to incorporate Environmental, Social, and Governance (ESG) principles through focused initiatives across its businesses
Launches collaborative centre for translational research in head and neck cancer
The company is committed to a new category development in areas like adult Immunization with products like Shingrix to make a positive impact to the lives of the patients in India
These re-agent and diagnostic test kits come with 99.7% accuracy
The 200 bedded hospital owned & operated by Alexis
Zydus’s revenue growth was led by India and EU formulations businesses in addition to that in the emerging markets.
EBITDA for Q3 FY24 almost tripled to reach Rs. 41.49 crore
Subscribe To Our Newsletter & Stay Updated
